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ABSTRACT
The health-related quality of life (HRQoL) is assessed using instruments that have been validated scientifically.
From the viewpoint of assessment, they are different from other clinical indices because the subjects them-
selves evaluate their own HRQoL (the patients in many clinical settings). As an index for evaluating health care
services or outcomes, the HRQoL is as important as life expectancy. These instruments can be classified into
generic and disease-specific instruments. There are numerous disease-specific instruments that can be used
for patients with asthma, such as Juniper et al .’s Asthma Quality of Life Questionnaire (AQLQ), the Living with
Asthma Questionnaire (LWAQ), the St. George’s Respiratory Questionnaire (SGRQ), and Marks et al . ’s
Asthma Quality of Life Questionnaire (AQLQ). The characteristics of each instrument should be considered in
the selection of specific HRQoL questionnaires for clinical research. Generally, the HRQoL is more disturbed in
patients with severe asthma, and has been considered to be an important end-point in randomized controlled
trials that involve asthma patients. We expect that further studies will also be performed in Japan．
KEY WORDS
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INTRODUCTION
Unfortunately, the term quality of life (QoL) is fre-
quently used as an abstract term in Japan. However,
it is commonly accepted in the health care services
and in relation to illness that QoL should be assessed
using scientifically established instruments , mostly
questionnaires.1-5 In general, the QoL is a compre-
hensive concept influenced by factors such as eco-
nomic status, occupation, and housing, which are not
directly related to the health status. In the fields of
health care services or in relation to health or illness,
the term health-related quality of life (HRQoL) is pre-
ferred.1
It is a well-known fact that an immense amount of
public resources is administered for health care serv-
ices all over the world. However, healthcare provid-
ers are largely unaware that they are consuming pub-
lic resources. Therefore, it is necessary to evaluate
these health care services. Improvements in life ex-
pectancy and HRQoL can be considered as clinical in-
dices for evaluating such an outcome. It would be
ideal if all medical interventions improved both life
expectancy and HRQoL. However , many practices
are actually performed on the presumption of improv-
ing these indices, and are based on experience rather
than scientific evidence . For assessing individual
treatment efficacy such as the effect of a drug, it is
necessary to consider the HRQoL assessment as an
outcome in randomized controlled trials.4 Moreover,
HRQoL assessment provides the fundamental data
for economic evaluation , for example cost-utility
analysis．
From the viewpoint of assessment , the subjects
themselves assess their own HRQoL, and it has been
shown that it is difficult for healthcare providers to
predict the HRQoL, even considering other clinical or
physiological information. In health care services, in-
formation obtained directly from subjects by inter-
views, self-reported questionnaires, or diaries is re-
ferred to as patient-reported outcomes (PROs) or self-
reported outcomes. The term PROs is used from the
viewpoint of assessment rather than the content. It
also raises the issue that many indicators for illness
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or health have been assessed by healthcare providers
rather than by the patients themselves. The HRQoL
is the best-known among the PROs.6
METHODS OF ASSESSMENT AND GENERIC
INSTRUMENTS
The HRQoL is assessed by using self- or interviewer-
administered questionnaires as instruments . 7 Al-
though various questionnaires have been advocated
and used as instruments depending on the purpose of
the assessment, the reliability, validity, and respon-
siveness of each questionnaire must be proven in or-
der to know whether the HRQoL can be assessed sci-
entifically. It usually requires a long-term patient ap-
proach to perform the scientific verification of an in-
strument．
The HRQoL in general should be assessed compre-
hensively, including several subscales. Each question
in a questionnaire is called an item, and domains, di-
mensions or components, which often consist of mul-
tiple items, correspond to each subscale (which is re-
ferred to as a profile). The HRQoL should include
components such as symptoms, functional capacity,
psychological status and social interactions. Further-
more, there is also a viewpoint that components such
as degrees of occupational and intellectual function,
economic aspects , and overall satisfaction , should
also be included. Depending on the specific purpose,
components that should be included are determined,
and their scores are calculated with or without
weighting, and then instruments are created in order
to express the measured results as numerical values.
When assessing the HRQoL in patients with a spe-
cific disease, either a generic or a disease-specific in-
strument can be selected depending on the purpose.
The greatest advantage of the former is that it can be
applied as an epidemiological approach. For example,
assessment by a generic instrument is necessary for
comparison between different diseases．
Generic instruments including the Sickness Impact
Profile (SIP), Nottingham Health Profile (NHP), and
SF (short-form)-36 of the Medical Outcomes Study
(MOS) have all been administered to patients with
asthma in the literature. The SIP has been used as
the standard questionnaire amongst the generic in-
struments in the past.8,9 However, the clinical applica-
tion of the SIP is complicated because it consists of
many items, and it takes a long time to complete. Al-
though the original purpose of the NHP developed in
the United Kingdom was to assess perceived distress,
10-12 it has been used by many researchers as a
method to assess the HRQoL. 13,14 The HRQoL as-
sessment in the MOS, an international project devel-
oped around the United States, often uses a method
with 36 items (short-form : SF-36).15 In studies on
chronic diseases, the SF-36 is the most used generic
instrument at the present.16 The Japanese version of
the SF-36 was established by Fukuhara and col-
leagues based on an analysis of the responses ob-
tained from a general population sample . 17,18 The
software for scoring is commercially available along
with the Japanese standard values, and they are very
convenient for end-users. The WHO first published
the WHOQOL-100, a questionnaire with 100 items,
and then the WHOQOL-BREF, an instrument with 26
items based on the former. The reliability and validity
of the Japanese version has also been reported．
The author would like to introduce an example of
using a generic instrument here.19 A comparison of
the HRQoL assessed with the NHP is illustrated in
Figure 1 for patients with asthma and chronic ob-
structive pulmonary disease ( COPD ) , and HIV-
infected persons . The NHP scores in the patients
with the former two diseases were investigated previ-
ously by this author. The other scores were obtained
from HIV-infected persons in Japan by Watanabe and
coworkers (The QoL Research Group of the AIDS
Clinical Center and eight Regional AIDS Treatment
hospitals in Japan supported by a Research Grant
from the Ministry of Health, Labour and Welfare of
Japan).19 Since it is well-known that the HRQoL is ad-
versely affected, COPD is a model disease for HRQoL
research. Even though the figure does not account
for age or gender , the NHP scores of the HIV-
infected persons are more severely affected than
those of the patients with asthma or COPD. In stud-
ies that compared the HRQoL of patients with asthma
versus patients with COPD using generic instru-
ments , the relative disturbance of patients with
asthma is usually milder than that of patients with
COPD. Moreover, in cross-sectional studies on pa-
tients with asthma, a deviation of the score distribu-
tion cannot be avoided when a generic instrument is
used．
In order to be used for pharmaco-economic evalu-
ation, including cost-utility analysis as well as quality-
adjusted life year (QALY) , a utility measure or a
preference-based measure is necessary. Japanese ver-
sions of the EQ5D (EuroQol) and Health Utility In-
dex (HUI) have been established for this purpose.
Since there are also many reports using the EQ5D in
chronic respiratory illnesses in western countries ,
there is a tendency to use it to measure outcomes for
economic evaluation in randomized controlled trials
in Europe and the United States．
DISEASE-SPECIFIC INSTRUMENTS IN
ASTHMA
In respiratory illnesses, there have been many stud-
ies investigating the HRQoL of patients with asthma
as well as COPD and lung cancers , and numerous
disease-specific instruments have been published
(Table 1). The American Thoracic Society has set up
the Quality of Life Resource (http:www.atsqol.org)
on its website, and listed instruments to assess the in-
dices related to QoL and symptoms. For adults with
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Fig. 1　Comparison of the Notingham Health Profile (NHP) scores in patients with asthma, chronic ob-
structive pulmonary disease (COPD) and HIV-infected persons in Japan. The NHP is a generic instru-
ment tentatively used for health-related quality of life (HRQoL) assessment, and consists of six subscales. 
A higher score indicates a greater disturbance in HRQoL.
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Table 1　Examples of disease-specific instruments in asthma used to measure the health-related quality of life (HRQoL).
Japanese 
version
responsivenessvalidityitems
available○○32Asthma Quality of Life Questionnaire-Juniper (AQLQ)
？○○32Standardized version of the AQLQ
？○○15Mini AQLQ
available ○○68Living with Asthma Questionnaire (LWAQ)
？？○27Modified and shortened version of the LWAQ
available○○50St. George’ sRespiratory Questionnaire (SGRQ)
？○○20Asthma Quality of Life Questionnaire-Marks (AQLQ)
available？○22＊Asthma Bother Profile (ABP)
available○○20Airways Questionnaire 20 (AQ20)
＊：15 items in Japanese version○━good, ?━ unknown.
asthma, 6 generic instruments and 12 disease-specific
instruments are listed. On the website operated by
MAPI Research Institute , a non-profit organization
with its headquarters in France, the Quality of Life In-
struments Database (http：www.qolid.org) can be
found, which lists 20 disease-specific instruments for
asthma in adults and children．
With respect to disease-specific instruments for
asthma , the Asthma Quality of Life Questionnaire
(AQLQ) published by Juniper and colleagues in 1992,
which consists of 32 items, is the best known and
most studied.20,21 Its responsiveness has also been re-
ported. The AQLQ consists of four domains : Symp-
toms (12 items), Activity limitations (11 items), Emo-
tional function (5 items), and exposure to environ-
mental stimuli (4 items). This instrument is similar to
the Chronic Respiratory Disease Questionnaire
(CRQ),22 which is a disease-specific instrument for
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Fig. 2　Comparison of the scores on the Activity component of the St. George’ sRespira-
tory Questionnaire (SGRQ) between groups based on their asthma severity as defined by 
the folowing stepwise therapeutic regimen of the British Thoracic Society guidelines 
(1993); Step 1: occasional use of relief bronchodilators; Step 2: Step 1 plus low-dose in-
haled corticosteroids, beclomethasone dipropionate (BDP-CFC) 200―800 μg or flutica-
sone propionate (FP) 100―400 μg daily; Step 3: Step 1 plus BDP at 800―2000 μg or FP 
400―1000 μg daily; Step 4: Step 3 plus regular bronchodilators; and Step 5: Step 4 plus 
daily oral corticosteroids.
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COPD developed at the same laboratory, and the re-
sponse option to each item can be selected from a
seven-point scale. Although the AQLQ was originally
published as an interview form, it is more commonly
used as a self-administered questionnaire today.7 The
smallest change of score that is clinically significant
is called the minimal clinical important difference
(MCID).23,24 When using the total score of each do-
main divided by the number of items in the AQLQ, it
has been reported that a difference of 0.5 is the
MCID for a score of 7. The Japanese version of the
AQLQ is supervised by the original authors.
In addition, each subject can select the kind of ac-
tivity for five items from the domain “activity limita-
tion”. In subsequent administrations, the same activ-
ity as in the previous questionnaire must be filled us-
ing the same items. This is classified as informed ad-
ministration, and it is impossible to avoid the compli-
cation of preparing previous questionnaires．
For this reason , a standardized version of the
AQLQ with five fixed items in the domain “activity
limitation” has been published.25 Moreover, Juniper
and associates published the Mini Asthma Quality of
Life Questionnaire (Mini AQLQ) in 1999. 26 It is a
self-administered short questionnaire with 15 items.
This reduces the number of items in each domain,
while keeping the four domains of the AQLQ. The
Japanese versions of these revised AQLQs have not
been reported．
On the other hand, the Living with Asthma Ques-
tionnaire ( LWAQ) developed by Hyland and col-
leagues in the United Kingdom has been frequently
used in European countries . 27,28 It consists of 68
items with 11 subscales, and the response for each
item can be selected from four options. The score is
divided by the number of items, except for items in
which the response is “not applicable”. The overall
score is between 0 and 2, and increases as the sever-
ity of the HRQoL disturbance increases. The Japa-
nese version has also been published．
When assessing the responsiveness of the LWAQ,
there are three methods of comparison within each of
the 11 domains, a comparison of the overall scores,
and a comparison between 49 items of problem con-
structs and 19 items of evaluation constructs . 29 A
method of assessing the responsiveness by dividing
an instrument into four or five subscales has also
been reported.30
Reid and colleagues reported the reliability and ap-
propriateness of a modified and shortened version of
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Fig. 3　Comparison of the scores on the Impact component of the St. George’ sRespira-
tory Questionnaire (SGRQ) between groups based on their asthma severity as defined by 
the folowing stepwise therapeutic regimen of the British Thoracic Society guidelines 
(1993); Step 1: occasional use of relief bronchodilators; Step 2: Step 1 plus low-dose in-
haled corticosteroids, beclomethasone dipropionate (BDP-CFC) 200―800 μg or fluticasone 
propionate (FP) 100―400 μg daily; Step 3: Step 1 plus BDP at 800―2000 μg or FP 400―
1000 μg daily; Step 4: Step 3 plus regular bronchodilators; and Step 5: Step 4 plus daily 
oral corticosteroids.
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the Living with Asthma Questionnaire (ms-LWAQ),31
which is a modified version of the LWAQ originally
created in the United Kingdom, to be more suitable
for use in the United States and with a reduced num-
ber of items . It consists of 5 subscales : Conse-
quences (10 items) , Affect (6 items) , Leisure ( 4
items), Seriousness (5 items), and Drugs (2 items).
The results of many studies that used the Asthma
Quality of Life Questionnaire developed by Marks
and coworkers in Australia have also been pub-
lished,32,33 and the verification of the Japanese ver-
sion was reported at a medical conference. In order
to distinguish it from Juniper’s questionnaire with the
same name, it is abbreviated in many ways, such as
AQLQ-M．
The St . George’s Respiratory Questionnaire
(SGRQ) developed by Jones and associates in the
United Kingdom is often used in patients with
COPD. 34,35 The validity and responsiveness have
also been confirmed in patients with asthma.36 The
SGRQ is a self-administered questionnaire with a total
of 50 items, and consists of 3 components : Symp-
toms (8 items), Activities (16 items), and Impacts (26
items). It is also possible to compute the total score.
Since weighting is performed to calculate the score of
the SGRQ, a manual with a computer is required for
the calculation. In general , “Activities ” may corre-
spond to dyspnea and physical functions, and “Im-
pacts ” to the components related to psychological
and social factors . It has been reported that the
MCID is 4 for a score of 100．
Hyland and coworkers developed the Asthma
Bother Profile (ABP), which consists of 15 “bother
items” and 7 “management items37 ”. Only “bother
items” are used in the Japanese version, and it is a
unidimensional instrument . 38 This instrument has
fewer items and can be self-reported easily. It should
be used as a tool for patient evaluation in a clinical
setting, but not as an index for the outcome of ran-
domized clinical trials . Similarly , Barley and col-
leagues developed the Airways Questionnaire 20 (AQ
20) as a questionnaire for the health status of patients
with asthma.39,40 Since there are only 20 items, it is a
short questionnaire that takes only a few minutes to
complete. However, it can be interpreted as a HRQoL
assessment in a broader sense.
The Japanese Society of Allergology is developing
a disease-specific instrument for patients with asthma
in Japan. In these studies, Arioka and associates de-
veloped an instrument with a total of 66 items, includ-
ing 29 items from the Functional Assessment of Can-
cer Therapy-General (FACT-G). The verification of its
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Fig. 4　Comparison of the total scores on the St. George’ sRespiratory Questionnaire 
(SGRQ) between groups based on their asthma severity as defined by the folowing step-
wise therapeutic regimen of the British Thoracic Society guidelines (1993); Step 1: occa-
sional use of relief bronchodilators; Step 2: Step 1 plus low-dose inhaled corticosteroids, 
beclomethasone dipropionate (BDP-CFC) 200―800 μg or fluticasone propionate (FP) 
100―400 μg daily; Step 3: Step 1 plus BDP at 800―2000 μg or FP 400―1000 μg daily; Step 
4: Step 3 plus regular bronchodilators; and Step 5: Step 4 plus daily oral corticosteroids.
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reliability and validity has just been completed．
An instrument is expected to have three proper-
ties : whether it can discriminate between subjects
(discriminative property),41 whether it can evaluate
small important changes (evaluative property―respon-
siveness or sensitivity), and whether it can predict fu-
ture results including the prognosis (predictive prop-
erty).42 However, only limited results have been re-
ported on comparative studies between the different
instruments used in patients with asthma.
RESEARCH RESULTS ON HRQoL IN
ASTHMA
The author would like to introduce the preliminary
results of a cross-sectional study on the HRQoL of
adult asthmatics. The SGRQ was administered in 314
consecutive patients who met the criteria of mild to
severe, stable asthma in an outpatient clinic. The cri-
teria for the patients with asthma were as follows :
over 18 years old , a history of asthma symptoms ,
follow-up at the clinic for more than 6 months, good
compliance with the clinical management based on
the British Thoracic Society (BTS) guidelines pub-
lished in 1993, including a daily measurement of their
peak expiratory flow rate (PEFR), and received the
same regimen for at least four weeks. We excluded
patients with apparent comorbidities which may af-
fect HRQoL. According to the BTS guidelines (1993),
the treatments were defined into the following five
steps : Step 1 : occasional use of relief bronchodila-
tors ; Step 2 : Step 1 plus low-dose inhaled corti-
costeroids, beclomethasone dipropionate (BDP-CFC)
200―800 μg or fluticasone propionate (FP) 100―400
μg daily ; Step 3 : Step 1 plus BDP at 800―2000 μg or
FP 400―1000 μg daily ; Step 4 : Step 3 plus regular
bronchodilators ; and Step 5 : Step 4 plus daily oral
corticosteroids. No patients were given long-acting β
agonist bronchodilators or any other inhaled corti-
costeroids except for BDP-CFC or FP dry powder in-
halation in the present analysis. Of the 314 patients
(150 men) (mean age : 49 yrs) with stable asthma,
the number of patients treated by the Step 1, 2, 3, 4
and 5 regimens according to the BTS guidelines 1993
were : 7 (5 men), 74 (29), 151 (78), 62 (28) and 20
(10) , respectively . The distributions of the scores
from the 314 patients with stable asthma on the
SGRQ are shown in Figures 2―4. The scores on the
Activity and Impacts components and the total score
on the SGRQ were similarly distributed, whereas the
scores were more or less skewed towards the milder
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Fig. 5　Box and whisker plots representing the score distribution of the total score from the St. George’ s
Respiratory Questionnaire (SGRQ) in patients with asthma and chronic obstructive pulmonary disease 
(COPD). The later data are cited from reference. 43 Both patients came from the same outpatient clinic.
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end of the scale. The severity of asthma defined by a
stepwise therapeutic regimen correlated significantly
with the Activity and Impacts score , and the total
score of the SGRQ. The total score on the SGRQ
could be compared with that obtained from patients
with COPD(Fig. 5).43 In patients with severe asthma,
the pattern of their score distributions on the total
score of the SGRQ was almost the same as the distri-
bution in patients with COPD. Therefore, it is demon-
strated that HRQoL disturbance is remarkable in pa-
tients with severe asthma, but less disturbed in mild
asthma.
In general, the relationship between the scores of
instruments that assess HRQoL in asthma patients
and physiological indices is quite low regardless of
whether it is evaluated cross-sectionally or longitudi-
nally, and regardless of whether generic or disease-
specific questionnaires are used. Many studies report
that the correlation coefficient between the scores of
each questionnaire and the FEV1 or PEF values is
around 0.3, and the relationship between airway re-
sponsiveness and the FEV1 or PEF values is not sig-
nificant. In other words, the factors that define the
HRQoL in asthma patients still remain largely un-
clear.
Van der Molen and colleagues compared the dis-
criminative properties of 2 generic questionnaires,44
the SF-36 and Psychological General Well Being
(PGWB) index, and 2 disease-specific questionnaires,
the AQLQ and LWAQ. They concluded that the dis-
criminative property was best in the AQLQ, and then
in the SF-36. Although there are some studies that
compared the discriminative properties of different
instruments, the results vary.45 It is more important
to select an instrument based on research purposes,
rather than because of its excellent discriminative
property.
The assessment of the HRQoL of patients with
asthma can be best applied in the assessment of treat-
ment efficacy in randomized controlled trials . 46-56
From the viewpoint of pharmaceuticals, the market
for anti-asthmatics is large , and new medications
have been continuously developed . Especially with
the marketing competition of new inhaled steroids
and leukotriene receptor antagonists in the 1990’s, in-
struments to assess HRQoL were used almost rou-
tinely as end-points in randomized controlled trials to
evaluate the effectiveness of medications and other
medical interventions in asthma patients . Although
morning PEF values are currently being used as the
primary end-points in clinical trials for asthma in
most cases, disease-specific instruments for asthma
with excellent responsiveness such as the AQLQ and
LWAQ tend to be used as secondary end-points．
An important issue has been identified about fol-
lowing the changes in the HRQoL, i .e. , responsive-
ness or sensitivity, by longitudinal examination with
generic instruments. Although sufficient comparative
studies between different instruments have not been
performed, it is thought that generic instruments are
less responsive than disease-specific instruments .
Ware and colleagues evaluated the responsiveness of
the SF-36 in asthma as changes in randomized con-
trolled trials, contrasting with Marks and colleague’s
Asthma Quality of Life Questionnaire , which is a
disease-specific instrument for asthma . 57 They re-
ported that the subscales “role-physical” and “physi-
cal functioning”, which represent real physical prob-
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lems, showed significant changes．
Juniper and colleagues evaluated the effects of sal-
meterol (50 μg, inhaled twice daily), salbutamol (200
μg, inhaled 4 times daily), and placebo on the HRQoL
in asthma, and the relationship with existing indices
of evaluation. 58 The trials were randomly-assigned,
placebo-controlled, double-blinded, and crossed-over
with 140 subjects , and were performed as a joint
study at multiple facilities for 12 weeks with 4 weeks
for each medication . During the period when sal-
meterol was administered , the AQLQ scores were
significantly improved as compared with the scores
during the periods of salbutamol or placebo admini-
stration ; however, the score difference between sal-
butamol and placebo administration was small. The
correlation coefficients of the changes in the overall
AQLQ scores and the difference between morning
and evening PEF values were 0.58 and 0.48, respec-
tively, and there was a moderately significant relation-
ship. The morning PEF values are currently used as
primary end-points in clinical trials on asthma pa-
tients in most cases. The relationship between the
change in morning PEF values and the changes in
HRQoL scores seems to be higher on the AQLQ than
on any other instruments . A correlation coefficient
over 0.5 obtained in this clinical trial can be inter-
preted as being substantially high．
The question of which disease-specific instrument
has the best responsiveness is related to the question
of which instrument should be used for randomized
controlled trials , and remains controversial . There
are several studies that evaluated the AQLQ and
LWAQ, which are disease-specific instruments , to
test which shows better responsiveness. In the clini-
cal trial to compare the effectiveness of salmeterol
(50 μg, inhaled twice daily) and salbutamol (400 μg,
inhaled twice daily ) , Rutten-van Molken and col-
leagues reported that there was no significant differ-
ence in the LWAQ scores, although the AQLQ scores
were significantly improved in the group with sal-
meterol administration.59 However, in the controlled
clinical trial to investigate the effectiveness of for-
moterol (24 μg, inhaled twice daily) against placebo,
van der Molen and colleagues reported that the
LWAQ scores were significantly improved although
the AQLQ scores were not . This discrepancy be-
tween the two results probably arose because the
subjects completed the questionnaires while looking
at their own responses from the last administration of
the questionnaire ( informed administration) in the
former study, while the subjects in the latter study
did not look at their previous responses while com-
pleting the questionnaires. In our previous study us-
ing the Japanese version, the responsiveness, defined
by the effect size or standardized response mean, of
Juniper’s AQLQ was superior to that of the LWAQ,
AQ20, SF-36, NHP or EQ5D.60,61
Hyland and colleagues have been focusing on the
fact that symptoms are often evaluated in the form of
diaries such as an asthma diary, and reported the ap-
propriateness of the structured asthma QOL diary to
assess HRQoL.62 They compared the QoL diary and
LWAQ in clinical trials, and reported that the former
had better responsiveness. Since diaries are a type of
informed administration, it is expected that responses
obtained through informed administration are related
to improved responsiveness. However, there is criti-
cism that this is not an appropriate use of the ques-
tionnaires.
In conclusion, the HRQoL is usually impaired in pa-
tients with moderate to severe asthma. An evaluation
of health care services as well as medical intervention
including pharmacotherapy should include the
HRQoL disturbed by disease . There are many ge-
neric and asthma-specific instruments available, and
specific instruments should be selected for the study
purpose. Since it is thought that the responsiveness
of the instruments is important in randomized-
controlled trials, Juniper’s AQLQ may be preferred．
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